LENZ Therapeutics Inc (LENZ) USD0.001
$0.31
(0.98%)
- Add to watchlist
- This stock can be held in a
$0.31
(0.98%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
$0.31
(0.98%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Business summary
LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.
Contact details
Important dates
General stock information
- Short code:
- LENZ
- ISIN:
- US52635N1037
- Market cap:
- $866.28 million
- Shares in issue:
- 27.50 million
- Sector:
- Biotechnology
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- NASDAQ Comb. Composite
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.